Tracie Overbeck, MD
Allergy & Immunology · Lexington, KYNPI 1881658805
Payments from drug & device makers
Across 727 payments — averaging $28.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- CSL Behring$4K
- Biocryst Pharmaceuticals, Inc.$3K
- Sanofi$2K
- GSK$1K
- Genentech USA, Inc.$740
- plus $7K from 32 others
What the payments were for
- Consulting fees$130%
- Speaking & faculty fees$3,50018%
- Travel & lodging$3452%
- Food & beverage$15,17679%
- Education$1961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 93 | $4,018 |
| CSL Behring | 96 | $3,539 |
| Biocryst Pharmaceuticals, Inc. | 11 | $2,691 |
| Sanofi | 77 | $1,935 |
| GSK | 61 | $1,099 |
| Genentech USA, Inc. | 30 | $740 |
| Pharming Healthcare, Inc. | 25 | $614 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $604 |
| Pfizer | 46 | $562 |
| Regeneron Healthcare Solutions, Inc. | 18 | $476 |
| Amgen | 31 | $465 |
| Kaleo, Inc. | 30 | $465 |
| Grifols USA, LLC | 21 | $460 |
| Novartis | 27 | $450 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $270 |
| Alk-abello, Inc | 11 | $266 |
| Shire North American Group Inc | 9 | $251 |
| Biocryst US Sales Co., LLC | 13 | $215 |
| LEO Pharma Inc. | 12 | $214 |
| Covis Pharma GmbH | 9 | $194 |
| Boehringer Ingelheim | 11 | $176 |
| Blueprint Medicines Corporation | 4 | $159 |
| AbbVie | 13 | $158 |
| Teva Pharmaceuticals USA, Inc. | 8 | $116 |
| Octapharma USA, Inc. | 4 | $108 |
| Optinose US, Inc. | 4 | $97 |
| Cycle Pharmaceuticals Inc | 3 | $92 |
| Ionis Pharmaceuticals, Inc. | 4 | $89 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Lilly USA, LLC | 4 | $69 |
| Azurity Pharmaceuticals, Inc. | 4 | $61 |
| Genentech, Inc. | 2 | $52 |
| Incyte Corporation | 2 | $33 |
| Arcutis Biotherapeutics, Inc. | 1 | $19 |
| Greer Laboratories, Inc. | 1 | $19 |
| Merck | 1 | $16 |
| ADMA Biomanufacturing LLC | 1 | $13 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,889 in reported general payments places this provider in the 70th percentile of 66 allergy & immunology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 11 | $525,560 |
| HaegardaC1 Esterase Inhibitor | 22 | $507,341 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $122,676 |
| Dupixent SyringeDupilumab | 25 | $110,628 |
| IcatibantIcatibant Acetate | 15 | $96,377 |
| Dupixent PenDupilumab | 12 | $46,779 |
| Spiriva RespimatTiotropium Bromide | 15 | $15,148 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $14,888 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $9,329 |
| DuleraMometasone/Formoterol | 18 | $9,237 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $8,250 |
| Epinephrine | 17 | $5,823 |
| Azelastine Hcl | 185 | $3,839 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,327 |
| Fluticasone Propionate | 143 | $2,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda, Hizentra | $3,539 | $630,01636 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $604 | $525,56011 claims |
| Boehringer IngelheimSpiriva Respimat | $176 | $15,14815 claims |
| AstraZenecaSymbicort | $4,018 | $14,88831 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $1,099 | $12,65625 claims |
| MerckDulera | $16 | $9,23718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 66 allergy & immunology providers in Kentucky.
Other allergy & immunology in Lexington
- William GreisnerLexington$1.8M
- Rajiv AroraLexington$144K
- Priya WarrierLexington$93K
- Shuya WuLexington$10K
- Shaunah RitterLexington$7K
- Alexander PattersonLexington$6K
- Kelsey CoyleLexington$3K
- Amy MashburnLexington$2K
- Leslie BranchLexington$1K
- John ThompsonLexington$258
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.